Soluble trivalent engagers redirect cytolytic T cell activity toward tumor endothelial marker 1-Reference-Cited by-同舟云学术

Soluble trivalent engagers redirect cytolytic T cell activity toward tumor endothelial marker 1

Published:2021-08 Issue:8 Volume:2 Page:100362
ISSN:2666-3791
Container-title:Cell Reports Medicine
language:en
Short-container-title:Cell Reports Medicine

Author:

Fierle Julie K.,Brioschi Matteo,de Tiani Mariastella,Wetterwald Laureline,Atsaves Vasileios,Abram-Saliba Johan,Petrova Tatiana V.,Coukos George,Dunn Steven M.

Funder

Ludwig Institute for Cancer Research

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference65 articles.

1. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia;Grupp;N. Engl. J. Med.,2013

2. Chimeric antigen receptor T cells for sustained remissions in leukemia;Maude;N. Engl. J. Med.,2014

3. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia;Porter;N. Engl. J. Med.,2011

4. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody;Bargou;Science,2008

5. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival;Topp;J. Clin. Oncol.,2011

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bispecific T-Cell Engagers (BiTEs) in Immunotherapy;Advances in Medical Diagnosis, Treatment, and Care;2024-08-28

2. Group XIV C-type lectins: emerging targets in tumor angiogenesis;Angiogenesis;2024-03-12

3. Targeting the activated microenvironment with endosialin (CD248)-directed CAR-T cells ablates perivascular cells to impair tumor growth and metastasis;Journal for ImmunoTherapy of Cancer;2024-02

4. Clinical Potential of YY1-Hypoxia Axis for Vascular Normalization and to Improve Immunotherapy;Cancers;2024-01-23

5. Endosialin in Cancer: Expression Patterns, Mechanistic Insights, and Therapeutic Approaches;Theranostics;2024